"It wasnt that long ago that it was thought impossible to target.... As we know PTX100 is, so far, the broadest spectrum of the Kras drugs."
According to Chat GPT:
The combination of a deeper understanding of KRAS biology, technological advancements in drug discovery, the development of mutation-specific inhibitors, covalent binding, innovative clinical trial designs, introduction of biomarkers and strong regulatory and industry support has led to the recent successes of KRAS-targeted drugs. These factors have collectively contributed to making KRAS inhibitors more effective now than in the past.
However, early resistance to targeted KRAS G12 mutations and also relapse due to resistance has been and still is an issue with some cancer types. The resistance seems to come about by the KRAS pathway inhibition leading to the stimulation of the downstream pathways. That is where PTX-100 is different. It targets the downstream pathways instead. PTX-100 goes after "the children" as SYC refers as opposed to going after the daddy of the mutated onogene.
What we also know from earlier Ph1 trials in breast cancer and ovarian cancer is that PTX-100 has a good safety profile and it shows clinical activity in these two indications. I wonder whether PTX-100 could even be considered as a candidate to combine with a KRAS G-12 drug to overcome the resistance issues that arise due to target specificity. Does PTX-100, though, in these indications require further dosage escalation trials to increase the clinical activity?
On the subject of broader application this is what ChatGPT presents in reply to the question: "Could PTX-100 be effective in the treatment of diseases beyond oncology?"
It also begs the question as to whether PTX-200 (also a pathway inhibitor) could have uses beyond cancer treatment... and whether PTX-100 and 200 could be a consideration for combo therapies??? Anything is possible given that newsflow has been stifled bar the surprise appointment of Dr Gavin Shepherd and his interest in PTX's IP.
PTX Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
